Parkinson's disease (PD) is the second most prevailing neurodegenerative disorder and is indicated by the degeneration of dopaminergic neurons within the substantia nigra; various categories of drugs aim to ensure the controlling of motor symptoms; nonetheless, the same will contribute to multiple side effects. This review dispatches a synopsis about physiopathology, clinical features, and etiology of PD and demonstrates the most common drug classes currently used in the management of PD as well as future treatment strategies. This review highlights the miscellaneous aims, targets, and drugs concerted during the years, for the management of PD. This assessment targets predominantly most of the drugs and chemical agents that have been used in treating PD and understanding their synthesis, uses (alone or in combination), and their imperfections. In this review, we have identified the current therapies used in treating PD patients along with the promising therapies for treatment of PD.